Information Provided By: 
Fly News Breaks for July 7, 2016
ELGX
Jul 7, 2016 | 08:31 EDT
As noted earlier, BMO Capital upgraded Endologix to Outperform from Market Perform. The firm says its survey of doctors indicate that the integration of TRIV is going well, while Nellix utilization is poised to rise to 20% of cases, up from 5% currently. The firm anticipates that Nellix will enable the company's revenue to rise by double digit percentage levels for several years. Target to $16 from $11.50.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
